167 related articles for article (PubMed ID: 11388542)
1. The cannabinoid agonist WIN55,212-2 suppresses opioid-induced emesis in ferrets.
Simoneau II; Hamza MS; Mata HP; Siegel EM; Vanderah TW; Porreca F; Makriyannis A; Malan TP
Anesthesiology; 2001 May; 94(5):882-7. PubMed ID: 11388542
[TBL] [Abstract][Full Text] [Related]
2. Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew.
Darmani NA; Janoyan JJ; Crim J; Ramirez J
Eur J Pharmacol; 2007 Jun; 563(1-3):187-96. PubMed ID: 17362921
[TBL] [Abstract][Full Text] [Related]
3. Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation.
Darmani NA; Sim-Selley LJ; Martin BR; Janoyan JJ; Crim JL; Parekh B; Breivogel CS
Eur J Pharmacol; 2003 Jan; 459(1):83-95. PubMed ID: 12505537
[TBL] [Abstract][Full Text] [Related]
4. The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2.
Darmani NA
Eur J Pharmacol; 2001 Oct; 430(1):49-58. PubMed ID: 11698062
[TBL] [Abstract][Full Text] [Related]
5. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats.
Rahn EJ; Makriyannis A; Hohmann AG
Br J Pharmacol; 2007 Nov; 152(5):765-77. PubMed ID: 17572696
[TBL] [Abstract][Full Text] [Related]
6. CB2 cannabinoid receptor-mediated peripheral antinociception.
Malan PT; Ibrahim MM; Deng H; Liu Q; Mata HP; Vanderah T; Porreca F; Makriyannis A
Pain; 2001 Sep; 93(3):239-245. PubMed ID: 11514083
[TBL] [Abstract][Full Text] [Related]
7. Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative.
Silva NR; Gomes FV; Fonseca MD; Mechoulam R; Breuer A; Cunha TM; Guimarães FS
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):369-377. PubMed ID: 28720466
[TBL] [Abstract][Full Text] [Related]
8. Involvement of CB1 receptors in the ventral tegmental area in the potentiation of morphine rewarding properties in acquisition but not expression in the conditioned place preference model.
Rashidy-Pour A; Pahlevani P; Vaziri A; Shaigani P; Zarepour L; Vafaei AA; Haghparast A
Behav Brain Res; 2013 Jun; 247():259-67. PubMed ID: 23511249
[TBL] [Abstract][Full Text] [Related]
9. Influence of intracerebroventricular administration of cannabinergic drugs on morphine state-dependent memory in the step-down passive avoidance test.
Zarrindast MR; Kangarlu-Haghighi K; Khalilzadeh A; Fazli-Tabaei S
Behav Pharmacol; 2006 May; 17(3):231-7. PubMed ID: 16572001
[TBL] [Abstract][Full Text] [Related]
10. Δ
Darmani NA; Belkacemi L; Zhong W
Eur J Pharmacol; 2019 Dec; 865():172806. PubMed ID: 31738934
[TBL] [Abstract][Full Text] [Related]
11. CB1 Cannabinoid Agonist (WIN55,212-2) Within the Basolateral Amygdala Induced Sensitization to Morphine and Increased the Level of μ-Opioid Receptor and c-fos in the Nucleus Accumbens.
Molaei M; Fatahi Z; Zaringhalam J; Haghparast A
J Mol Neurosci; 2016 Apr; 58(4):446-55. PubMed ID: 26803309
[TBL] [Abstract][Full Text] [Related]
12. The effects of different antiemetic agents on morphine-induced emesis in ferrets.
Wynn RL; Essien E; Thut PD
Eur J Pharmacol; 1993 Sep; 241(1):47-54. PubMed ID: 8223924
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoid CB1 receptors of the dorsal hippocampus are important for induction of conditioned place preference (CPP) but do not change morphine CPP.
Zarrindast MR; Nouri M; Ahmadi S
Brain Res; 2007 Aug; 1163():130-7. PubMed ID: 17631872
[TBL] [Abstract][Full Text] [Related]
14. The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain.
Fox A; Kesingland A; Gentry C; McNair K; Patel S; Urban L; James I
Pain; 2001 May; 92(1-2):91-100. PubMed ID: 11323130
[TBL] [Abstract][Full Text] [Related]
15. Agonist-dependent cannabinoid receptor signalling in human trabecular meshwork cells.
McIntosh BT; Hudson B; Yegorova S; Jollimore CA; Kelly ME
Br J Pharmacol; 2007 Dec; 152(7):1111-20. PubMed ID: 17922024
[TBL] [Abstract][Full Text] [Related]
16. Role of cannabinoid CB1 receptors and Gi/o protein activation in the modulation of synaptosomal Na+,K+-ATPase activity by WIN55,212-2 and delta(9)-THC.
Araya KA; David Pessoa Mahana C; González LG
Eur J Pharmacol; 2007 Oct; 572(1):32-9. PubMed ID: 17644088
[TBL] [Abstract][Full Text] [Related]
17. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret.
Van Sickle MD; Oland LD; Ho W; Hillard CJ; Mackie K; Davison JS; Sharkey KA
Gastroenterology; 2001 Oct; 121(4):767-74. PubMed ID: 11606489
[TBL] [Abstract][Full Text] [Related]
18. Pre-emptive antinociceptive effects of a synthetic cannabinoid in a model of neuropathic pain.
Guindon J; Desroches J; Dani M; Beaulieu P
Eur J Pharmacol; 2007 Jul; 568(1-3):173-6. PubMed ID: 17555742
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effect of cannabinoid agonists on gastric emptying in the rat.
Izzo AA; Mascolo N; Capasso R; Germanò MP; De Pasquale R; Capasso F
Naunyn Schmiedebergs Arch Pharmacol; 1999 Aug; 360(2):221-3. PubMed ID: 10494894
[TBL] [Abstract][Full Text] [Related]
20. Topical cannabinoid agonist, WIN55,212-2, reduces cornea-evoked trigeminal brainstem activity in the rat.
Bereiter DA; Bereiter DF; Hirata H
Pain; 2002 Oct; 99(3):547-556. PubMed ID: 12406531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
